menu
    • menu
    [{"orgOrder":0,"company":"Geha Mental Health Center","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Thrombin","moa":"Coagulation factor XI; Coagulation factor XIII A chain; Coagulation factor XIII B chain; Fibrinogen alpha chain; Fibrinogen beta chain; Fibrinogen gamma chain; Coagulation factor V; Coagulation factor VIII; Proteinase-activated receptor 1; Proteinase-activated receptor 4","graph1":"Oncology","graph2":"Phase III","graph3":"Geha Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Geha Mental Health Center \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Geha Mental Health Center \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"H\u00f4pital du Sacre-C\u0153ur de Montr\u00e9al","sponsor":"Baxter Healthcare Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Thrombin","moa":"Coagulation factor XI; Coagulation factor XIII A chain; Coagulation factor XIII B chain; Fibrinogen alpha chain; Fibrinogen beta chain; Fibrinogen gamma chain; Coagulation factor V; Coagulation factor VIII; Proteinase-activated receptor 1; Proteinase-activated receptor 4","graph1":"Hematology","graph2":"Phase IV","graph3":"H\u00f4pital du Sacre-C\u0153ur de Montr\u00e9al","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"H\u00f4pital du Sacre-C\u0153ur de Montr\u00e9al \/ Baxter Healthcare Corporation","highestDevelopmentStatusID":"11","companyTruncated":"H\u00f4pital du Sacre-C\u0153ur de Montr\u00e9al \/ Baxter Healthcare Corporation"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"The Ottawa Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Thrombin","moa":"Coagulation factor XI; Coagulation factor XIII A chain; Coagulation factor XIII B chain; Fibrinogen alpha chain; Fibrinogen beta chain; Fibrinogen gamma chain; Coagulation factor V; Coagulation factor VIII; Proteinase-activated receptor 1; Proteinase-activated receptor 4","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Spray","sponsorNew":"Unity Health Toronto \/ The Ottawa Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Unity Health Toronto \/ The Ottawa Hospital"},{"orgOrder":0,"company":"Aronora","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Thrombin","moa":"Coagulation factor XI; Coagulation factor XIII A chain; Coagulation factor XIII B chain; Fibrinogen alpha chain; Fibrinogen beta chain; Fibrinogen gamma chain; Coagulation factor V; Coagulation factor VIII; Proteinase-activated receptor 1; Proteinase-activated receptor 4","graph1":"Hematology","graph2":"Phase I","graph3":"Aronora","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aronora \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aronora \/ Undisclosed"},{"orgOrder":0,"company":"Ethicon","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Thrombin","moa":"Coagulation factor XI; Coagulation factor XIII A chain; Coagulation factor XIII B chain; Fibrinogen alpha chain; Fibrinogen beta chain; Fibrinogen gamma chain; Coagulation factor V; Coagulation factor VIII; Proteinase-activated receptor 1; Proteinase-activated receptor 4","graph1":"Hematology","graph2":"Phase IV","graph3":"Ethicon","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ethicon \/ Johnson & Johnson","highestDevelopmentStatusID":"11","companyTruncated":"Ethicon \/ Johnson & Johnson"},{"orgOrder":0,"company":"Ethicon","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Thrombin","moa":"Coagulation factor XI; Coagulation factor XIII A chain; Coagulation factor XIII B chain; Fibrinogen alpha chain; Fibrinogen beta chain; Fibrinogen gamma chain; Coagulation factor V; Coagulation factor VIII; Proteinase-activated receptor 1; Proteinase-activated receptor 4","graph1":"Hematology","graph2":"Phase IV","graph3":"Ethicon","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ethicon \/ Johnson & Johnson","highestDevelopmentStatusID":"11","companyTruncated":"Ethicon \/ Johnson & Johnson"}]

    Find Clinical Drug Pipeline Developments & Deals for Thrombin

    Menu

    Thrombin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aronora

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Aronora

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thrombin

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects

                            Details : Thrombin is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Thrombosis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 05, 2018

                            Lead Product(s) : Thrombin

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Unity Health Toronto

                            Country arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Unity Health Toronto

                            Country arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thrombin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Undisclosed

                            Sponsor : The Ottawa Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With (HHT)

                            Details : Thrombin is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Telangiectasia, Hereditary Hemorrhagic.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 22, 2015

                            Lead Product(s) : Thrombin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Undisclosed

                            Sponsor : The Ottawa Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ethicon

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Ethicon

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thrombin

                            Therapeutic Area : Hematology

                            Study Phase : Phase IV

                            Sponsor : Johnson & Johnson

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Bioseal Vascular Study

                            Details : Thrombin is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hemorrhage.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 24, 2014

                            Lead Product(s) : Thrombin

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase IV

                            Sponsor : Johnson & Johnson

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ethicon

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Ethicon

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thrombin

                            Therapeutic Area : Hematology

                            Study Phase : Phase IV

                            Sponsor : Johnson & Johnson

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase IV Bioseal Study in Brain Tumor Surgery

                            Details : Thrombin is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hemostasis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 14, 2014

                            Lead Product(s) : Thrombin

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase IV

                            Sponsor : Johnson & Johnson

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Geha Mental Health Center

                            Country arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Geha Mental Health Center

                            Country arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thrombin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Baxter Healthcare Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Prevention of Pelvic Lymphocele by Floseal During Pelvic Lymphadenectomy for Gynecologic Cancer

                            Details : Floseal (Thrombin) is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Genital Neoplasms, Female.

                            Product Name : Floseal

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 01, 2013

                            Lead Product(s) : Thrombin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Baxter Healthcare Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Hôpital du Sacre-Cœur de Montréal

                            Country arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Hôpital du Sacre-Cœur de Montréal

                            Country arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thrombin

                            Therapeutic Area : Hematology

                            Study Phase : Phase IV

                            Sponsor : Baxter Healthcare Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Compare the Addition of Floseal to Our Standard of Care to Control Post Operative Bleeding in TKR

                            Details : Floseal (Thrombin) is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hemorrhage.

                            Product Name : Floseal

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 03, 2013

                            Lead Product(s) : Thrombin

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase IV

                            Sponsor : Baxter Healthcare Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth